Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH₂ derivative of levofloxacin in rats

References

• Andreas L, Jeroen B. 2002. Differences in caffenine and paraxanthine metabolism between human and murine CYP1A2. Biochem Pharmacol 63(12):2159–2167.
   PubMedGoogle Scholar
• Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR. 1995. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 39(3):305–311.
   PubMedGoogle Scholar
• Elliot VH, Paul AM. 2004. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 135:298–311.
   PubMedGoogle Scholar
• Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. 2004. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 76(5):598–606.
   PubMedGoogle Scholar
• Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. 2000. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 356(9274):2069–2070.
   PubMedGoogle Scholar
• Hersh EV, Moore PA. 2004. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 135(7):845.
   Google Scholar
• Hiroshi I, Yasuhiro T, Shigetoshi K, Akira H, Tadashi W. 2005. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from evodia fruit extract. Drug Metab Pharmacokinet 20(1):34–45.
   PubMedGoogle Scholar
• Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ. 2003. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 58(10):653–657.
   PubMedGoogle Scholar
• Kingzig-Schippers M, Fuhr U, Zaigler M, Dammeyer J, Rüsing G, Labedzki A, Bulitta J, Sörgel F. 1999. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther 65(3):262–274.
   PubMedGoogle Scholar
• Koboyashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, Kuroiwa Y. 1998. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 45:361–368.
   PubMedGoogle Scholar
• Kunii T, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Inoue Y, Otani K. 2005. Interaction study between enoxacin and fluvoxamine. Therapeut Drug Monit 27(3):349–353.
   PubMedGoogle Scholar
• Liu XQ, Zhao Y, Li D, Qian ZY, Wang GJ. 2003. Metabolism and metabolic inhibition of clinipine in human liver microsomes. Acta Pharmacologica Sinica 24(1):263–268.
   PubMedGoogle Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with Folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• Maesen FP, Teengs JP, Baur C, Davies BI, 1984. Quinolones and raised plasma concentrations of theophylline. Lancet ii(8401):530.
   Google Scholar
• Nakamura H, Ohtsuka T, Enomoto H, Hasegawa A, Kawana H, Kuriyama T, Ohmori S, Kitada M. 2001. Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy. Ann Pharmacother 35(6):691–693.
   PubMedGoogle Scholar
• Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. 2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Disposit 29(10):1316–1324.
   PubMed Web of Science ®Google Scholar
• Pang XY, Xie L, Xu X, Liu HY, Liu L, Liu XD. 2007. Pharmacokinetics of antofloxacin in rats coadministered with non-steroidal anti-inflammatory drugs. Chin J New Drugs 16(8):600–603. [in Chinese]
   Google Scholar
• Parker AC, Preston T, Heaf D, Kitteringham NR, Choonara I. 1994. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol 38(6):573–576.
   PubMedGoogle Scholar
• Raaska K, Neuvonen PJ. 2000. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 56(8):585–589.
   PubMedGoogle Scholar
• Richter T, Murdter TE, Heinkele G, Pleiss J, Tazel S, Schwab M, Eichelbaum E, Zanger UM. 2004. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308(1):189–197.
   PubMedGoogle Scholar
• Ron EP. 1989. Drug–drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 87(5):S76–S81.
   Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414–423.
   PubMed Web of Science ®Google Scholar
• Shiraki H, Guengerich FP. 1984. Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase and epoxide hydrolase. Archiv Biochem Biophys 235(1):86–96.
   PubMedGoogle Scholar
• Silverman RB. 1988. Mechanism-based enzyme inactivation: chemistry and enzymology. Boca Raton, FL: CRC Press.
   Google Scholar
• Tarrus E, Cami J, Roberts DJ, Spickett RG, Celdran E, Segura J. 1987. Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23(1):9–18.
   PubMedGoogle Scholar
• Wijnands WJ, Vree TB, Van Herwaarden CL. 1986. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 22(6):677–683.
   PubMedGoogle Scholar
• Xiao Y, Lu Y, Kang Z, Hou F, Wang S, Li T, Liu Y, Xia Y. 2008a. Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int J Clin Pharmacol Therapeutics 46(4):172–179.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Zhang M, Li T. 2008b. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharmaceut Drug Disposit 29(3):167–172.
   PubMed Web of Science ®Google Scholar
• Xu X, Liu HY, Liu L, Xie L, Liu XD. 2008. The influence of a newly developed quinolone: antofloxacin. on CYP activity in rats. Eur J Drug Metab Pharmacokinet 33(1):1–7.
   PubMedGoogle Scholar
• Ye H, Wu JM, Yang YS, Chen KX, Ji RY. 2002. Antibacterial activities of the dirivatives-YH54 and YH57 of levofloxacin in vitro. China Pharmacol Bull 18(1):112–113.
   Google Scholar
• Zhang H, Fang Y, Wang SJ. 2005. Simultaneous determination of blood drug concentration of acetaminophen and phenacetin by HPLC. China Pharma 16(8):608. [in Chinese]
   Google Scholar